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Disclaimer 
 
 
Certain commercial equipment, instruments, and materials are identified in 
this report to specify adequately the experimental procedure. In no case does such identification 
imply recommendation or endorsement by the European Commission, nor does it imply that the 
material or equipment is necessarily the best available for the purpose. 
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Summary 
This report describes the production of ERM-DA474/IFCC, a human serum material certified 
for C-reactive protein mass concentration. The material has been produced following ISO 
Guide 34:2009 [1]. 
Serum was produced from blood collected in 4 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low. The serum was processed, spiked with C-reactive protein, ampouled and 
frozen. 
Between unit-heterogeneity has been quantified and stability during dispatch and storage 
have been assessed in accordance with ISO Guide 35:2006 [2]. 
The material was characterised by an intercomparison among laboratories of demonstrated 
competence. Technically invalid results were removed but no outlier was eliminated on 
statistical grounds only.  
Uncertainties of the certified value were calculated in compliance with the Guide to the 
Expression of Uncertainty in Measurement (GUM) [3] and include uncertainties related to 
possible heterogeneity and instability and to characterisation. 
The material is intended for the calibration of immunoassays. As any reference material, it 
can also be used for control charts or validation studies. The CRM is available in glass 
ampoules containing 1 mL of human serum closed under argon atmosphere. The minimum 
amount of sample to be used is 20 µL. 
The CRM has been accepted as European Reference Material (ERM®) after peer evaluation 
by the partners of the European Reference Materials consortium. 
The following value was assigned: 
 
Mass concentration 
 Certified value 2) 
[mg/L] 
Uncertainty 3) 
[mg/L] 
C-reactive protein (CRP)1 41.2 2.5 
1) CRP as measured by immunonephelometry and immunoturbidimetry using ERM-DA470 as calibrant (Baudner et al., 
EUR reports 15423 and 16882 European Communities, Luxembourg (1993)), applying the procedures described for the 
certification of ERM-DA472/IFCC, ERM-DA470 and 1st Int. St. for CRP Code 85/506. 
2) The value is the unweighted mean of 6 accepted mean values, independently obtained by 4 laboratories. The 
certified mass concentration is traceable to the SI, via ERM-DA470. 
3) The certified uncertainty is the expanded uncertainty with a coverage factor k = 2 corresponding to a level of 
confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of Uncertainty 
in Measurement (GUM 1995), ISO, 2009. 
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Glossary 
 
smeasν  Degrees of freedom for the determination of the standard deviation smeas 
MSwithinν  Degrees of freedom of MSwithin 
x  Arithmetic mean of all results of a study  
α Significance level 
ANOVA  Analysis of variance 
b Slope in the equation of linear regression y = a + bx 
Bit Unit of the anallog-to-digital converter of the light detector 
C Mass concentration c = m / V (mass / volume) 
C3c Complement 3c 
C3 Complement 3 
CASO Casein soy bean 
CRM Certified reference material 
CRP C-reactive protein 
EC European Commission 
ERM® Trademark of European Reference Materials 
FPLC Fast protein liquid chromatography 
g Relative centrifugal force 
HBV Hepatitis B virus 
HBsAg Hepatitis B surface antigen 
HCV Hepatitis C virus 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
hs High sensitivity 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IRMM Institute for Reference Materials and Measurements  
ISO International Organization for Standardization  
IU International Unit 
IVD In Vitro Diagnostics 
JRC Joint Research Centre 
k Coverage factor 
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KIU Kallikrein Inhibitor Unit 
m Mass 
MS Mass spectrometry 
MSbb Mean sum of squares between bottles 
MSbetween Mean squares between-unit from an ANOVA 
MSwb Mean sum of squares within bottles 
MSwithin  Mean squares within-unit from an ANOVA 
MWCO Molecular weight cut-off 
n Number of replicates per unit 
N Number of samples (units) analysed 
n.a. Not applicable 
ND Not detectable 
p Number of accepted datasets 
PAGE Polyacrylamide gel electrophoresis 
QC Quality control 
rel Index denoting relative figures (uncertainties etc.) 
RM Reference Material 
RM Unit Reference Materials Unit 
RF Rheumatoid factors 
RSD Relative standard deviation 
RSE Relative standard error (=RSD/√n) 
r2 Coefficient of determination of the linear regression 
s Standard deviation 
sbb
 Between-unit standard deviation; an additional index "rel" is added as 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SDS Sodium dodecyl sulphate 
SI International System of Units 
smeas Standard deviation of measurement data; an additional index "rel" is 
added as appropriate 
swithin Standard deviation within groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
swb Within-unit standard deviation 
tα, df Critical t-value for a t-test, with a level of confidence of 1-α and df 
  6 
degrees of freedom 
tsl Proposed shelf life 
TM Target material 
TF Transfer factor 
TRIS Tris(hydroxymethyl)aminomethane 
u Standard uncertainty  
U Expanded uncertainty 
uc Combined standard uncertainty; an additional index "rel" is added as 
appropriate 
u*bb  Standard uncertainty related to a maximum between-unit heterogeneity 
that could be hidden by method repeatability; an additional index "rel" is 
added as appropriate 
ubb Standard uncertainty related to a possible between-unit heterogeneity;  
an additional index "rel" is added as appropriate 
uchar  Standard uncertainty of the material characterisation; an additional 
index "rel" is added as appropriate 
uCRM Standard combined uncertainty of a certified value; an additional index 
"rel" is added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
ults Standard uncertainty of the long-term stability; an additional index "rel" 
is added as appropriate 
um Measurement uncertainty 
Umeas Expanded measurement uncertainty 
urec  Standard uncertainty related to possible between-unit heterogeneity 
modelled as rectangular distribution; an additional index "rel" is added 
as appropriate 
usts Standard uncertainty of the short-term stability 
u∆ Combined standard uncertainty of measurement result and certified 
value 
ti Time point for each replicate 
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1 Introduction  
1.1 Background: need for the CRM  
C-reactive protein (CRP) is an important analyte in clinical chemistry. It is a very sensitive 
marker of inflammation and tissue damage [4]. Routine clinical uses of CRP results include 
the diagnosis of bacterial and viral infections and the assessment of disease activity in 
inflammatory conditions like rheumatoid arthritis. 
CRP was originally discovered by Tillett and Francis in 1930 as a substance in the serum of 
patients with acute inflammation that had the capacity to precipitate the C polysaccharide of 
Pneumococcus [5] . In the blood of healthy young adult blood donors, the median mass 
concentration of CRP is 0.8 mg/L, the 90th centile is 3.0 mg/L, and the 99th centile is 10 
mg/L. Following an acute-phase stimulus, values may increase to more than 500 mg/L [4]. 
The finding that modest but persistently increased values are associated with a long-term 
risk for coronary heart disease [6] has led to the development of assays specifically designed 
to measure relatively low concentrations of CRP. These assays are often called high 
sensitivity CRP (hs CRP) assays. 
The immunoassays used for CRP measurements are capable of a high degree of analytical 
sensitivity and selectivity, and are convenient in a clinical setting because they give fast 
results. They are based on the fact that when the antigen (CRP) and specific antibodies are 
brought together they form complexes or aggregates that scatter incident light. The 
scattering of the light is measured by turbidimetry (measuring the reduction of light passing 
through a reaction mixture) or nephelometry (measuring the light scattered by a reaction 
mixture). The signal is dependent on a large number of factors such as antibody specificity, 
reaction kinetics and equilibria, multimeric state of the proteins, matrix effects, etc. The 
quantification with immunoassays is therefore entirely dependent on the comparison of the 
results with those obtained with a calibrant [7]. 
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) [8] 
requires traceability of the assigned values of calibrants and control materials to reference 
measurement procedures and/or reference materials of higher order. 
In 1989 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
began the processing, characterisation, and calibration of a matrix reference material for 
human serum proteins. In 1993 the Bureau Communautaire de Référence released the 
resulting CRM 470 (later renamed to ERM-DA470), certified for 15 proteins [9]. The protein 
concentration measurements done for the value assignment of CRP in ERM-DA470 were 
calibrated with the 1st International Standard CRP 85/506. 
After the release of ERM-DA470 IVD manufacturers began referencing their calibrants and 
controls to the material, and the between-laboratory variation for assays of serum proteins 
became substantially lower for most of the proteins certified in ERM-DA470 [10, 11]. 
In 2008, ERM-DA472/IFCC was produced to replace ERM-DA470 for the CRP mass 
concentration [12]. The present material has been produced to replace ERM-DA472/IFCC. 
1.2 Choice of the material 
The requirements for a material to be used as a reference material for serum protein 
immunoassays are, next to requirements for homogeneity, stability and metrological 
traceability: 
o the material should behave like fresh patient serum samples (commutability) 
o the certified mass concentration of the protein in the final material should be high 
enough so that dilutions of the material can cover the relevant part of the 
measurement interval of the assays 
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o the material should be optically clear. This property is important, as most clinical 
immunoassays use optical measurement methods. This means that the material must 
have a low content of lipids and lipoproteins. 
Therefore it was decided to process the new material according to procedures similar to 
those applied for ERM-DA472/IFCC [12]. 
1.3 Design of the project 
Serum was produced from blood collected in 4 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low. 
Twelve small pilot batches were produced by spiking serum with recombinant CRP or CRP 
isolated from pleural fluids under different conditions (method for buffer exchange between 
dialysis and diafiltration, addition of Ca2+ before or after spiking the CRP, addition of sucrose 
in the final material). The pilot batches were used to verify the recovery for CRP depending 
on the protocol. With the most suitable protocol, two additional pilot batches were produced 
to check the scaling up of the procedure to larger volumes. On that basis, it was decided to 
process the main part of the serum and to spike the material with CRP isolated from pleural 
fluids. 
The serum was processed in 2 batches, then pooled and spiked with CRP. The serum was 
filled in ampoules, which were afterwards stored at -70 °C. 
The material was characterised through a value transfer procedure [13]. The characterisation 
measurements were calibrated using ERM-DA470 [9]. In this procedure, ERM-DA474/IFCC 
is used to determine the response curve of the instrument, and the 6 dilutions of ERM-DA470 
are measured directly against different dilutions of ERM-DA474/IFCC.  
The techniques used to measure the protein concentrations were nephelometry and 
turbidimetry. The measurements were performed with different instruments (Abbott Architect 
c16000, Beckman Synchron, Siemens BNTM II, Siemens BN ProSpec®, Siemens Dimension 
Vista®, Hitachi 917, Roche Integra 800 and Roche Cobas c501) and reagents. In total five 
laboratories participated in the value assignment. The characterisation measurements were 
done under an ISO 13485 quality system. 
2 Participants 
2.1 Project management and evaluation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No 268-TEST) 
2.2 Provision of serum and proteins 
Blutspendedienst SRK Bern, Bern, CH 
Etablissement Français du Sang, Rhône-Alpes, Valence, FR 
Hralec Králové University Hospital, Hralec Králové, CZ 
Siemens Healthcare Diagnostics Products GmbH, Marburg, DE 
University College London (UCL), Medical School, London, UK 
2.3 Processing, homogeneity and stability study 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No 268-TEST) 
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Siemens Healthcare Diagnostics Products GmbH , Marburg, DE (measurements under the scope 
of ISO 13485 certification TÜV Rheinland 60038820) 
2.4 Characterisation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No 268-TEST) 
Beckman Coulter, Brea, US (measurements under the scope of ISO 13485 certification NSAI MD 
19.2791/2) 
DAKO Denmark, Glostrup, DK (measurements under the scope of ISO 13485 certification UL A12312) 
Roche Diagnostics GmbH, Penzberg, DE (measurements under the scope of ISO 13485 certification 
TÜV SÜD 00 07 45096 005) 
Sentinel CH. S.p.A., Milano, IT (measurements under the scope of ISO 13485 certification BSI MD 
504781) 
Siemens Healthcare Diagnostics Products GmbH , Marburg, DE (measurements under the scope 
of ISO 13485 certification TÜV Rheinland 60038820) 
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3 Material processing and process control 
 
3.1 Origin of the starting material 
The starting material for the reference material was a serum pool prepared from the blood of 
healthy donors, collected at four different blood collection centres (Table 1) as well as 
unprocessed serum as used for ERM-DA470k/IFCC [14]. 
Selection of the donors: 
o Sex   both sexes 
o Age   20 – 70 years 
o Blood group   known 
o RF    < 30 IU/mL 
o Monoclonal components  not detectable (checked by zone electrophoresis) 
o Bilirubin serum colour  visually normal 
o Hemoglobin serum colour  visually normal 
o Lipemia   no turbidity observed 
o Infectious agents negative for  HBsAg, anti HIV 1, anti HIV 2, syphillis and  
anti HCV 
Serum collection protocol: 400 – 500 mL blood was withdrawn from each donor, expected to 
give an average serum volume of 180 mL (140 – 220 mL). 
The following protocol was applied for preparing the serum: 
a) Pre-prandial blood (tourniquet used). 
b) Collection into a dry bag or a polymer bottle, not containing any additives or anticoagulant 
(such as Baxter, Fenwal). 
c) Clotting at room temperature for 3-4 hours. 
d) Centrifugation of the bag in a centrifuge bucket or a bottle at 2200 g for 20 minutes. 
e) Separation of the serum from the clot.  
f) 40 aliquots of 0.5 mL were taken from each donor for testing. 
g) Freezing of the serum between -70 and -80 °C. 
h) Discarding of donations positive for infectious agents. 
i) Transport of the serum to IRMM on dry ice, storage at -70 °C. 
j) Discarding of donations with RF> 30 IU/mL and/or presenting monoclonal components. 
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Table 1 : Summary information on the collected serum. The number of donations not fulfilling 
the inclusion criteria is given in parenthesis. 
Collection Centre Donation 
period 
Number 
of 
donors 
Male Female RF > 
30 
IU/mL 
Monoclonal 
components 
Final 
Number 
Blutspendedienst 
SRK Bern AG 
(CH) 
18/05/2009 
to 
05/06/2009 
60 39 (2) 21 (0) 1 2 58 
Etablissement 
Français du Sang 
– Rhône-Alpes 
(FR) 
08/01/2007 
to 
23/01/2007 
40 27 (0) 13 (0) 0 0 40 
Hradec Králové 
University 
Hospital (CZ) 
16/06/2009 
to 
23/06/2009 
60 29 (0) 31 (1) 1 0 59 
Siemens 
Healthcare 
Diagnostics 
Products GmbH 
(DE) 
24/09/2009 60 50 (1) 10 (0) 0 1 59 
 
Tests of the serum : The blood collection centres tested each donations for HIV 1+2, HBV or 
HBsAg and HCV. Monoclonal gammopathies were detected by gel electrophoresis. Two 
donations were discarded because of the presence of monoclonal components, one donation 
was discarded because the Rheumatoid Factor (RF) concentration was above 30 IU/mL and 
one donation presenting both the presence of monoclonal components and a RF 
concentration above 30 IU/mL was discarded. 216 donations, of which 75 originated from 
female donors, were fulfilling the inclusion criteria, and were released for further processing. 
3.2 Processing of the serum 
Overview of the procedure 
The processing procedure has been adapted from the procedures that were used for 
ERM-DA470 as described in the certification report [9] and ERM-DA472 with respect to the 
final aggregate state and filling [12]. As in the original procedure [12] dialysis was used for 
buffer exchange after delipidation with Aerosil. The dialysis buffer was supplemented with 
CaCl2 to maintain its physiological concentration. 
3.2.1 Preparation of pools 
Donations fulfilling the above criteria were processed as described below: 
o thawing at 5 ± 3 °C (2 to 3 days) 
o determination of the volume of each donation 
o Pool 1: pooling of all suitable CH and CZ donations 
o Pool 2: pooling of all suitable donations of the DE, FR and 104 50 mL-aliquots taken 
before processing from the individual batches used to produce the 
ERM-DA470k/IFCC [14]. 
o addition of sodium azide (Merck, Darmstadt, DE) to a final concentration of 7.7 mM 
(approx. 0.5 g/L) 
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o removal of aliquots for the measurement of cholesterol, triglycerides, 
apolipoprotein A-I, apolipoprotein B, total protein (Biuret reaction) and for the 
measurement and physicochemical analysis of selected proteins 
The material is now in State A 
Conversion of C3 to C3c 
o adjustment of pH to 7.2 ± 0.1 with saturated HEPES buffer (Calbiochem, Merck 
Biosciences, Schwalbach, DE) 
o addition of 20 mM magnesium acetate tetrahydrate (Merck, Darmstadt, DE) 
o adjustment of the solution to 37 °C 
o addition of Inulin (Sigma Aldrich, Milwaukee, USA) to a final concentration of 0.2 % 
o stirring for 1.5 to 2 hours at 37 °C 
Delipidation with Aerosil 
o adjustment of inulin-treated pool to pH 8.5 ± 0.1 with saturated TRIS solution (Sigma-
Aldrich, Milwaukee, USA) 
o addition of sodium chloride (crystalline; Merck, Darmstadt, DE) to 50 g/L of the pool 
while stirring constantly 
o calculation of the required amount of Aerosil 200 (Degussa, Frankfurt, DE) based on 
the total protein concentration of the pool before C3 treatment (approx. 430 mg/g total 
protein) 
o gradual addition of Aerosil while stirring and constantly monitoring and if necessary 
adjusting the pH to 8.5 ± 0.1 
o continued slow stirring for another 30 minutes 
o removal of Aerosil and protein precipitates by centrifugation for 30 minutes at 
approximately 10000 g using 500 mL-centrifuge bottles 
o determination of the total volume of the clear supernatant 
o determination of cholesterol, triglycerides and apolipoproteins A-I and B to verifiy the 
successful lipid removal 
Sterile filtration and dialysis 
o filtration of the supernatant using a 0.45 µm Sartobran P filter (Sartorius, Göttingen, 
Germany) to remove small particles interfering with the following dialysis 
o before dialysis removal of aliquot for the measurement of CRP, IgG and total protein 
(Biuret reaction) 
o dialysis (Visking, Typ 36/32, MWCO 12000-14000) using isotonic saline with 2.5 mM 
CaCl2 over 2 to 4 days at +2 °C to +8 °C with a 2-fold buffer exchange (sample/buffer 
ratio 1:15) 
o removal of aliquots for the measurement of IgG and total protein (Biuret reaction). 
o ultrafiltration (MWCO 10000) to adjust the concentration to 8 to 10 g/L IgG and to 55 
to 75 g/L for total protein. 
Material is now in State B 
Preservation and sterile filtration 
o adjustment of the pH with saturated HEPES solution to 7.2 ± 0.1 
o addition of sodium azide to a final concentration of 14.6 mM (0.95 g/L) 
o addition of aprotinin to 80000 KIU/L (8 mL Trasylol 500 000 KIU/L, Bayer, 
Leverkusen, DE) 
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o addition of benzamidine chloride monohydrate (Merck, Darmstadt, DE) to a final 
concentration of 1 mM 
o adjustment of the pH with saturated HEPES solution to 7.2 ± 0.1 
o sterile filtration using a Sartopore 2 filter (0.2 µm) (Sartorius, Göttingen, DE) 
o sterile removal of 
• 600 mL of Pool 1 (used to produce pilot batches) 
• 300 mL of Pool 2 (used to produce pilot batches) 
o sterile removal of aliquots for the measurement of total protein (Biuret reaction), CRP, 
and physicochemical analysis 
Material is now in State C. 
Until processing of the final pool the material was stored below -70 °C. 
Protein concentration measurements: Throughout the processing, the mass 
concentrations of CRP, IgG, apolipoprotein A-I and B were determined by 
immunonephelometry on a BN ProSpec® or BN™ II System using reagents, standards 
and controls of Siemens Healthcare Diagnostics Products GmbH. 
Total protein determination : Determination of total protein was done according to the 
Biuret method using pure human serum albumin (internal Siemens product) for the 
calibration and chemicals from Merck (Darmstadt, DE) or Sigma-Aldrich (Milwaukee, 
USA). 
Lipids : Cholesterol was measured using the cholesterol CHOD-PAP Kit and triglycerides 
with the Triglycerides GPO Kit (Roche Diagnostics, Mannheim, DE). 
Blank signal : According to the specifications for the instrument concerned an empty 
cuvette is considered adequately inserted and optically clear if the scattered light gives a 
signal between 20 and 600 Bit (unit of the anallog-to-digital converter of the light 
detector). 
3.2.2 Preparation of the combined pool 
Preparation of CRP 
A purified (as described in [15]) human CRP solution (CRP mass fraction 97 % of total 
protein; CRP mass concentration 3.88 g/L) was used. The material was stored below -70 °C 
and thawed in a water bath at 37 °C with occasional turning. Before spiking the pool, the 
CRP solution was gently mixed while avoiding turbulence. 
Preparation of the final material 
o thawing of both pools (6 days) at 5 ± 3 °C 
o pooling 
o ultrafiltration 
o measurement of the CRP mass concentration 
o preparation of the CRP solution as described 
o slow addition of the CRP solution while constantly stirring 
o pH adjustment with saturated HEPES solution (pH 7.2 ± 0.1) 
o sterile filtration (0.2 µm) 
o sterile removal of aliquots for further analysis, including sterility testing 
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3.2.3 Processing control 
Processing of the two pools 
Total protein concentration: In line with the protocol for the preparation of the original ERM-
DA470 only pools with a total protein concentration between 60 and 80 g/L were considered 
to qualify as starting material for the processing, and after Aerosil treatments, the pools 
should be adjusted to protein concentrations between 55 and 75 g/L. As shown in Table 2, 
the total protein mass concentration of the pools was 77.3 and 81.1 g/L in State A and 54.4 
and 57.6 g/L in State C respectively, i.e. within the defined tolerance limits (taking into 
account the uncertainties for the measurement, the slightly higher value for pool 1 in State A 
was considered acceptable). 
Table 2: Total protein mass concentration (Biuret method) of pools at the different processing 
stages 
 State A State B State C 
Pool Total protein [g/L] Total protein [g/L] Total protein [g/L] 
1 81.1 44.9 57.6 
2 77.3 42.5 54.4 
 
Delipidation: The delipidation by the Aerosil treatment is considered successful when the 
relative mass concentrations of cholesterol and apolipoprotein B are reduced to 1 % of the 
concentration in the starting material. The relative mass concentrations for triglycerides and 
apolipoprotein A-I should be below 15 % and 20 % of the starting material, respectively. As 
shown in Table 3, these criteria were fulfilled for both pools.  
Table 3: Lipoprotein mass concentrations before processing and after Aerosil treatment1 
 State A State B 
Pool 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
1 1910 1122 1500 714 8.4 73.4 ND ND 
2 1254 803 1495 852 2.8 60.4 ND ND 
1when the concentration is below the limit of detection this is marked ND (not detectable)  
The reduction of the blank value obtained by measuring the signal of undiluted sample using 
a Siemens BNA System also demonstrated the effective removal of lipoproteins (Table 4). 
Table 4: Signal measured with a nephelometer before and after Aerosil treatment 
 
Measurement value 
[Bit] 
Pool State A State C 
1 3626 49 
2 3883 55 
 
Preparation of the combined pool 
Mixing of the two pools: Pool 1 and 2 were mixed to give the final material pool for the further 
material processing. 
  15 
Sterility test: The sterility of the material was verified by inoculating Casein Soy Bean (CASO) 
Digest Broth with the sterile filtrated pool, and streaking it out on CASO agar, Blood agar and 
McConkey agar (Institut für Medizinische Mikrobiologie und Krankenhaushygiene, University 
of Giessen and Marburg, Marburg, DE). No growth was observed on the selected media after 
five days, and the pool was released for filling. 
Blank values: The blank value for the final pool before sterile filtration was 93 Bit (detector 
values), after sterile filtration 84 Bit, and the material could thus be considered as optically 
clear. 
3.3 Filling and labelling 
The serum was ampouled at IRMM in a single batch. Approximately 1 mL (at least) of serum 
was filled into 3 mL Duran glass ampoules using a Rota ampouling machine R 910 PA (Rota, 
Wehr, DE). The ampouling machine and the cooled serum were placed in a movable class 
1000 cleanroom (Terra Universal Inc., Fullerton, California, USA). The ampoules were first 
opened, flushed with argon, filled with 1 mL of serum, flushed with argon and flame sealed. 
During the filling, the bottle containing the serum was kept at low temperature in a tray filled 
with ice/water under continuous stirring. The transfer lines were made of Teflon®. The speed 
of the ampouling machine was adapted to minimise the formation of foam in the ampoules. 
Care was taken that no serum was heated up during the closing of the ampoules. Some 
ampoules had a black spot on top linked to the presence of droplets of serum falling on the 
ampoule after filling. The ampoules were scrutinised and the ones presenting black spots of 
burnt serum were discarded. After filling, the ampoules were kept at +4 °C and labelled 
according to the filling order. Thereafter, the material was frozen at -70 °C. 
After processing, selected samples were analysed with semi-native gel electrophoresis 
(1/20 SDS-PAGE) followed by Western Blotting in order to check the absence of monomeric 
CRP in ERM-DA474/IFCC. No evidence of the presence of monomeric CRP was found thus 
proving that no degradation of the pentameric CRP occurred during the processing. 
4 Assessment of homogeneity 
A key requirement for any reference material is the equivalence between the various units. In 
this respect, it is not relevant whether the variation between units is significant compared to 
the analytical variation, but whether this variation is significant to the certified uncertainty. 
Consequently, ISO Guide 34 requires RM producers to quantify the between-unit variation. 
This aspect is covered in between-unit homogeneity studies. 
4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified values of the CRM 
are valid for all units of the material, within the stated uncertainty.  
For the between-unit homogeneity test, 30 units were selected using a random stratified 
sampling scheme covering the whole batch. For this, the batch was divided into 30 groups 
(with similar number of units) and one unit was randomly selected from each group. The 
number of selected units corresponds to approximately the cubic root of the total number of 
the produced units. From each unit, six independent samples were taken and analysed by 
immunonephelometry. The analyses were performed in a randomised manner to be able to 
separate a potential analytical drift from a trend in the filling sequence. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. Some significant (99 % confidence level) trends in 
the analytical sequence were observed (see Annex A - Figure A-1). As the analytical 
sequence and the unit numbers were not correlated, correction for these trends can improve 
the sensitivity of the subsequent statistical analysis through a reduction in analytical variation 
without masking potential between-unit heterogeneities. Therefore, trends in the analytical 
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sequence were corrected as the trend was significant on at least a 99 % confidence level as 
shown in formula (1). 
corrected result = measured result – b x i (1) 
b = slope of the linear regression 
i = position of the result in the analytical sequence 
A high dispersion of the results was noted for the first two runs. A Cochran test for variance 
presented the variance from the first run as an outlier thus confirming that the variation within 
the run was not only due to the lack of homogeneity of the samples. As a consequence, this 
first run was not retained for the calculations. The second run was not presenting any 
outlying variance and was retained for further calculations. 
The trend-corrected dataset was tested for consistency using Grubbs outlier tests on a 
confidence level of 99 % on the individual results and the unit means. Some outlying 
individual results and outlying unit means have been detected. Since no technical reason for 
the outliers could be found, all the data were retained for statistical analysis with the 
exception of the first run. 
Quantification of between-unit heterogeneity is most easily done by analysis of variance 
(ANOVA), which can separate the between-unit variation (sbb) from the within-unit variation 
(swb). The latter is equivalent to the method repeatability if the individual samples are 
representative for the whole unit.  
Evaluation by ANOVA requires unit means which follow at least a unimodal distribution and 
results for each unit that follow unimodal distributions with approximately the same standard 
deviations. Distribution of the unit means was tested using histograms and normal probability 
plots. Too few data are available for each unit to make a clear statement of the distribution of 
individual results. Therefore, it was checked whether all individual data follow a unimodal 
distribution using histograms and normal probability plots. Minor deviations from unimodality 
of the individual values do not grossly affect the estimate of between-unit standard 
deviations.  
One has to bear in mind that sbb,rel and swb,rel are estimates of the true standard deviations 
and therefore subject to random fluctuations. Therefore, the mean squares between groups 
(MSbetween) can be smaller than the mean squares within groups (MSwithin), resulting in 
negative arguments under the square root used for the estimation of the between-unit 
variation, whereas the true variation cannot be lower than zero. In this case, u*bb, the 
maximum heterogeneity that could be hidden by method repeatability, was calculated as 
described by Linsinger et al. [16]. u*bb is comparable to the limit of detection of an analytical 
method, yielding the maximum heterogeneity that might be undetected by the given study 
setup.  
Method repeatability (swb,rel), between–unit standard deviation (sbb,rel) and u*bb,rel were 
calculated as  
y 
within
rel,wb
MS
s =  
y
n
MSMS
s
withinbetween
rel,bb
−
=  
y
νn
MS
u
MSwithin
within
*
rel,bb
4
2
=  
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MSwithin mean squares within a unit from an ANOVA  
MSbetween  mean squares between-unit from an ANOVA 
y  average of all results of the homogeneity study 
n average number of replicates per unit 
MSwithinν   degrees of freedom of MSwithin  
The results of the measurements are shown in Annex A. The results of the evaluation of the 
between-unit variation are summarised in Table 5. 
Table 5: Results of the homogeneity study 
Measurand  
swb,rel  
[%]
 
sbb,rel  
[%]
 
u*bb,rel 
[%] 
ubb,rel 
[%] 
CRP mass 
concentration 
1.38 0.69 0.22 0.69 
 
The homogeneity study showed no outlying unit means or trends in the filling sequence. 
Therefore the between-unit standard deviation can be used as estimate of ubb. As u*bb sets 
the limits for the detection power of the study, the larger value of sbb and u*bb is adopted as 
uncertainty contribution to account for potential heterogeneity. 
4.2 Within-unit homogeneity and minimum sample intake 
The material is in solution and is not expected to have any relevant heterogeneity. This 
assumption was confirmed by the homogeneity/stability/characterisation study, where 
sample intakes as low as 20 µL were found to give acceptable repeatabilities, demonstrating 
that there is no intrinsic heterogeneity or contamination at a sample intake of 20 µL. 
Therefore the minimum sample intake is 20 µL. 
5 Stability 
Time and temperature were regarded as the most relevant influences on the stability of the 
materials. 
Stability testing is necessary to establish conditions for storage (long-term stability) as well as 
conditions for dispatch to the customers (short-term stability). During transport, especially in 
summer time, temperatures up to 60 °C can be reached and stability against these 
conditions must be demonstrated if transport at ambient temperature will be applied. 
The stability studies have been carried out using an isochronous design [17]. In that 
approach, samples are stored for a certain time at different temperature conditions. 
Afterwards, the samples are moved to conditions where further degradation can be assumed 
to be negligible ("reference conditions"), effectively "freezing" the degradation status of the 
materials. At the end of the isochronous storage, the samples are analysed simultaneously 
under repeatability conditions. Analysis of the material (after various exposure times and 
temperatures) under repeatability conditions greatly improves the sensitivity of the stability 
tests.  
5.1 Short-term stability study 
For the short-term stability study, samples have been stored at -20°C, 4 °C, 18 °C and 60 °C 
for 0, 1, 2 and 4 weeks (at each temperature). The reference temperature was set to -70 °C. 
Two units per storage time were selected using a random stratified sampling scheme. From 
each unit, three samples were measured by immunonephelometry. The measurements were 
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performed under repeatability conditions, and in a randomised manner to be able to separate 
a potential analytical drift from a trend over storage time. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends according to the time and the temperature. Some significant (99 % 
confidence level) trends in the analytical sequence were observed (Annex B - Figure B-1). As 
the analytical sequence and the unit numbers were not correlated, correction for these trends 
can improve the sensitivity of the subsequent statistical analysis through a reduction in 
analytical variation without masking potential between-unit heterogeneities. Therefore, as a 
significant trend in the analytical sequence was noted, the results were corrected using the 
formula (1) explained in paragraph 4.1.  
The obtained data were evaluated individually for each temperature. The results were 
screened for outliers using the single and double Grubbs test. Some outlying individual 
results were found but as no technical reason for the outliers could be found all data were 
retained for statistical analysis. 
Furthermore, the data were plotted against storage time and regression lines of mass 
concentration versus time were calculated. The slope of the regression lines was then tested 
for statistical significance (loss/increase due to shipping conditions). For CRP, the slopes of 
the regression lines were not significantly different from 0 (at 95 and 99 % confidence level) 
for -20 °C, 4 °C and 18 °C. The samples stored at 60 °C were clotted and, therefore, no 
analysis of the CRP mass fraction was possible.  
The results of the measurements are shown in Annex B.  
No technically unexplained outliers were observed and none of the trends with storage time 
was statistically significant on a 99 % confidence level for any of the temperatures.  
The material was found stable at -20 °C, 4 °C and 18°C. Nevertheless, the material is stored 
frozen and therefore freeze/thaw cycles should be kept at minimum. With this consideration, 
the material shall be shipped frozen on dry ice. 
5.2 Long-term stability study 
For the long-term stability study, samples have been stored at -20 °C and -70 °C for 0, 4, 8 
and 12 months (at each temperature). The reference temperature was below -150 °C. Two 
units per storage time were selected using a random stratified sampling scheme. From each 
unit, three samples were measured by immunonephelometry. The measurements were 
performed under repeatability conditions, and in a randomised manner to be able to separate 
a potential analytical drift from a trend over storage time. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. Some significant (95 % confidence level) trends in 
the analytical sequence were observed (Annex C - Figure C-1). As the analytical sequence 
and the unit numbers were not correlated, correction for these trends can improve the 
sensitivity of the subsequent statistical analysis through a reduction in analytical variation 
without masking potential between-unit heterogeneities. Therefore, as a significant trend in 
the analytical sequence was noted, the results were corrected using the formula (1) 
explained in paragraph 4.1. 
The obtained data were evaluated individually for each temperature. The results were 
screened for outliers using the single and double Grubbs test. Some outlying individual 
results were found but as no technical reason for the outliers could be found all data were 
retained for statistical analysis.  
Furthermore, the data were plotted against storage time and regression lines of mass 
concentration versus time were calculated. The slope of the regression lines was then tested 
for statistical significance (loss/increase due to storage conditions). For all elements, the 
slopes of the regression lines were not significantly different from 0 (on 95 and 99 % 
confidence level) for both -70 °C and -20 °C.  
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The results of the measurements are shown in Annex C. 
No technically unexplained outliers were observed and none of the trends was statistically 
significant on a 99 % confidence level for any of the temperatures. The material will be stored 
at -70 °C. 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results no study can rule out degradation of 
materials completely, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation that could be hidden by the method 
repeatability, i.e. to estimate the uncertainty of stability. This means, even under ideal 
conditions, the outcome of a stability study can only be "degradation is 0 ± x % per time".  
Uncertainties of stability during dispatch and storage were estimated as described in [18]. 
For this approach, the uncertainty of the linear regression line with a slope of zero is 
calculated. The uncertainty contribution (ults) is then calculated as the product of the chosen 
shelf life and the uncertainty of the regression lines as 
( ) slirellts
t
xx
RSD
u ⋅
−
=
∑
2,
 
RSD  relative standard deviation of all results of the stability study 
ti time point for each replicate 
x  mean results for all time points  
tsl proposed shelf life (12 months at -70 ºC in this case) 
The following uncertainty was estimated: 
• usts,rel, the uncertainty of degradation during dispatch. This was estimated from the  
-20 °C study for a time of 1 month (4 week). The uncertainty therefore describes the 
possible change during a dispatch on dry ice lasting for one week where the 
temperature in the parcel may reach -20 °C. 
• ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the -70 °C study. The uncertainty contribution therefore describes the possible 
degradation for 12 months at -70 °C.  
The results of these evaluations are summarised in Table 6. 
Table 6: Uncertainties of stability during storage and dispatch. usts,rel was calculated for a 
temperature of -20 °C and 1 week; ults,rel was calculated for a storage temperature of -70 °C 
and 1 year. 
Measurand usts ,rel 
[%] 
ults,rel 
[%] 
CRP mass 
concentration 
0.11 % 0.61 % 
 
After the certification campaign, the material will be subjected to IRMM's regular stability 
monitoring programme to control its further stability. 
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6 Characterisation 
6.1 Selection of participants 
Five laboratories were selected based on criteria that comprised both technical competence 
and quality management aspects. Each participant was required to operate a quality system 
and to deliver documented evidence of its laboratory proficiency in the field of element 
measurements in relevant matrices by submitting results for intercomparison exercises or 
method validation reports. Having a formal accreditation was not mandatory, but meeting the 
requirements of ISO/IEC 17025 was obligatory. The measurements were performed under a 
ISO 13485 quality management system and the certification number is stated in the list of 
participants (Section 2). Furthermore all the selected laboratories have successfully 
participated to past certification projects for the same measurand in the same matrix. 
6.2 General principles 
The characterisation of CRP in the human serum reference material ERM-DA474/IFCC is 
performed according to the principles as documented in [13] and [19]. The characterisation is 
achieved by transferring values from ERM-DA470 to the candidate reference material. ERM-
DA470 is certified for its CRP mass concentration. It is diluted at different concentrations that 
are measured as samples in the measuring system. The dose-response function of the 
measuring system is determined by using dilutions of the candidate reference material. 
The practical transfer protocol is based on duplicate measurements of 6 dilutions of ERM-
DA470 and 6 dilutions of the candidate reference material under conditions as repeatable as 
possible. The transfer protocol requires several measurements a day (three in this study) 
repeated on several days (four in this study), an important prerequisite being that all 
reconstitutions and dilutions are controlled by weighing, thus reducing uncertainty in the 
transfer. 
With regard to the transfer procedure, the following definitions apply ([13] and [19]): 
The reference preparation (ERM-DA470) is defined as the protein preparation with known 
concentration value (Table 7).  
Table 7: Certified value and expanded uncertainty of CRP in the calibrant ERM-DA470 [9] 
Certified value1) [mg/L] UCRM2) [mg/L] 
39.2 1.9 
1) In the reconstituted material. The certified value is the unweighted mean of 3 accepted mean values, 
independently obtained by 3 laboratories. 
2) The certified expanded uncertainty is the half-width of the 95 % confidence interval of the mean defined in 
footnote 1) 
Target material is defined as the serum protein matrix material with unknown concentration 
value. In this case it is the new matrix material ERM-DA474/IFCC. 
The transfer method should be based on well established and recognised methods used in 
clinical chemistry. In this characterisation study immuno-turbidimetry, and immuno-
nephelometry were used. 
Slight variations in the assay conditions, in the programming of the instruments or in the 
reagents may lead to different results. This has lead to the prerequisite of method 
standardisation [7]. To minimise all of these factors contributing to variation, an optimised 
and practical transfer protocol was made with detailed instructions and emphasis on 
weighing all solutions used to prepare dilutions. To record the obtained data, special 
registration forms were made also containing the intended dilution schemes. These raw data 
forms were subsequently sent for data treatment.  
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When assigning a value to a target material (a serum) using an existing reference material 
the value transfer procedure is used [13]. In this procedure dilutions of the target material are 
used to determine the dose-response function for the instrument or the assay. Dilutions of 
ERM-DA470 are then measured against this calibration curve in the following way: 
1. 6 different dilutions are prepared of the target material (TM). The concentration of the 
specific protein (although still unknown) in each dilution will be: 
  CTM(i)  =  FTM(i) x CTM  (2) 
 where FTM is the dilution factor of TM and (i) denotes the different dilutions (i = 1-6). 
2. A series of 6 test samples are prepared by diluting increasing amounts of the reference 
material to 6 different test tubes. The final volume of all preparations is then adjusted to 
be the same by adding a dilution solution (usual diluent used for each assay). The 
dilutions are made in such a way that the signals will fall within the signal interval of the 
dose-response curve. The concentration of the samples will be: 
   CS(j)  =  F470(j) x C470  (3) 
 where F470 is the dilution factor of ERM-DA470 and (j) denotes the different dilutions 
(e.g., j =1-6). 
3. A dose-response function is determined by using the dilutions of TM, and by plotting the 
signals against the different dilutions of TM. 
4. In a sample run the different dilutions of ERM-DA470 are measured. The signals of these 
test samples SS(j) are interpolated on the dose-response curve. The resulting 
concentrations CS(j) are now obtained as relative concentrations of TM: 
   CS(j)  =  FTM(j) x CTM  (4) 
5. Since the unknown concentrations in CS(j) can be either calculated using equation (3) or 
found by interpolation on the dose-response curve (4), a combination of (3) and (4) will 
give: 
   CS(j)  = FTM(j) x CTM = F470(j) x C470 
   FTM(j)  = C470 / CTM  x  F470(j) (5) 
 which is the equation of a straight line (y = α x). 
6. The different dilution factors FTM(j) obtained by the interpolation are now plotted against 
the different dilution factors F470(j) used for the initial dilution of ERM-DA470. Since all 
dilutions are controlled by weighing the uncertainty of F470(j) is negligible. 
The slope (α) is equal to the ratio of the concentrations of the specific protein in the two 
materials: 
  α = C470 / CTM  (6) 
 Since the slope can easily be calculated, the unknown concentration CTM is now found to 
be: 
 CTM = C470 / α  (7) 
The final characterisation study was conducted using ERM-DA470 to assign values to ERM-
DA474/IFCC. The methods including instruments, dilution buffers, antibodies and reagents 
and laboratories are listed in Annex D. 
Each of the 4 days a new ampoule of the reference preparation and the target material is 
used and a new set of dilutions is prepared. Each day 3 calibrations are performed together 
with determinations of samples and controls (i.e., 3 runs). 
Additionally, on each run, duplicate measurements of a specific dilution of the same target 
material used for the calibration were assessed as control values (measured concentration of 
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CRP in a control dilution of ERM-DA474/IFCC relative to the concentration in the control 
sample expected on the basis of the dilution, calculated from the mass values obtained by 
weighing). 
The transfer procedure was optimised separately for each measuring system participating in 
the value assignment. The dilution scheme was optimised taking into account that dilutions 
automatically carried out by the instruments should be avoided as much as possible (as 
these dilutions cannot be corrected by more accurate weighings). Finally it had to be 
stressed that for each material all 6 dilutions should be prepared from a single vial and that 
all reconstitutions and dilutions are controlled by weighing. 
6.3 Calculation of the dilutions 
The liquids used for the reconstitution of the materials and for the preparation of the dilutions 
were weighed to a standard deviation of maximum 0.0001 g. 
The density of the solutions were either provided by the participating laboratories or 
measured on a DMA 4500 M densitometer (Anton Paar, Graz, AT). 
The following mass corrections were applied: 
For the reconstitution: 
iM,
intended
iM,
m
mf =  
Where intendedm  is the mass intended to be added (1.0000 g), and iM,m  is the measured mass 
of water added to the vial. 
In case of predilutions: 
iPD,
iPD,
iPR,
iPR,
iPR,
iPR,
iP,
ρρ
ρ
mm
m
f
+
=  
Where iPR,m and iPD,m  are the masses of the reconstituted material and of the diluent for the 
predilution and iPR,ρ and iPD,ρ  are the density of the reconstituted material and of the diluent 
for the predilution. 
For the dilutions: 
iDD,
iDD,
iDM,
iDM,
iDM,
iDM,
ijD,
ρρ
ρ
mm
m
f
+
=  
For the dilution j of the material i with iDM,m  and iDM,ρ  respectively the mass and the density 
of the reconstituted material (prediluted or not), and iDD,m  and iDD,ρ  respectively the mass 
and the density of the diluent for dilution j. 
The concentration cij (with c = m/V (mass / volume) and the unit mg/L) of CRP in the dilutions 
is calculated via: 
ijDfffcc ,×××= iP,iM,0iij  
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With c0i being the concentration of CRP in material i and cij the concentration of CRP in 
dilution j of the material i. 
6.4 Data analysis 
A variety of measurement instruments existing in the field (8) with different quantification 
principles (nephelometry and turbidimetry), different dilution buffers, antibodies and reagents 
were used to characterise the material. 
All methods used during the characterisation study are summarised in Annex D. The 
laboratory code (e.g., L1) is a random number and does not correspond to the order of 
laboratories in Section 2.4. The lab-method code consists of a number assigned to each 
laboratory (e.g., L1) and the dataset number, (e.g., Dataset 1). 
Datasets were defined as the combination of the triplicate measurements performed on four 
days by each participant (i.e., up to 12 measurements). 
6.4.1 Technical evaluation 
For the value transfer procedure, the laboratories used the dilutions to construct the 
calibration curve directly. The values entered into their instrument for the concentration of 
these dilutions were the values of the concentration relative to the concentration in  
ERM-DA474/IFCC, expressed in percent. These relative concentrations were calculated from 
the masses of the solutions (and predilution if relevant). Then for each run, the laboratories 
measured the dilutions of ERM-DA470 in duplicate. 
The measured values Sijk (signal of the kth measurement of material i within dilution j) were 
plotted in scatter plots Sijk = f(cij) so as to evaluate outliers. Outliers were only rejected if there 
was a technical reason for doing so (a transcription error, wrong dilution, etc.). A linear 
regression with intercept was performed on the means of the Sijk in function of the 
concentration cij. 
The following specific acceptance criteria were applied for the open procedure: 
The mean control value is within 1.00 ± 0.05 
The following analyses were performed on all data: 
o testing for normality (visual inspection and normal probability plot) 
o testing for linearity (visual inspection and evaluation of r2) 
o verification that the intercept ± 4 times the standard deviation covers the origin. 
The following general acceptance criteria were applied to the datasets: 
o r2 of the regression must be above 0.98 for all measurement systems 
o Data from at least four dilutions must be available 
o The completeness of data must be at least 50 % for the data of a particular day. 
Otherwise the data from that day are declared non-valid 
o At least two daily value assignments must be valid 
o The day-to-day variation (RSD) of valid datasets for a particular laboratory must be 
equal to or below 5 % 
Rationale for the acceptance criteria (see also reference [13]): 
o Non-overlapping confidence intervals of the intercepts of regressions are either an 
indication of differing matrix effects or of quality problems of measurements resulting 
in scattering, both of which would result in non-valid results. 
o Overall r2 < 0.98 of regression indicates quality problems in the measurements 
(scattering, outliers, run-to-run variation). 
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Based on the above some datasets were rejected as not technically valid (see Table 8). 
Among all the determinations, four runs were rejected on basis of the control value falling 
outside of the above-mentioned specifications. 
The results for two laboratories (L3 and L5) presented an intercept significantly different from 
0 for all the 12 individual determinations and the whole datasets were therefore not included 
in the calculation. 
Nine individual results presented an intercept significantly different from 0 and were not 
retained. As a result, only one valid dataset remained for one day and was discarded 
because less than two results were obtained for that specific day. 
Table 8: Datasets that showed non-compliances with the analysis protocol and technical 
specifications, and action taken. 
Property 
measured 
Lab-method code Description of problem Action taken 
L1-Dataset 1 
day 1 – run 3 
QC sample out of specification not used for 
evaluation 
L5 – Dataset 8 
Day 2 – run 1,2 
and 3 
QC sample out of specification not used for 
evaluation 
L3 – Dataset 5 
all days – all runs 
Intercept significantly different from 
0 
not used for 
evaluation 
L5 – Dataset 8 
all days – all runs 
Intercept significantly different from 
0 
not used for 
evaluation 
L3 – Dataset 6 
Day 1 – run 2 and 
3 
Intercept significantly different from 
0 
not used for 
evaluation 
L3 – Dataset 6 
Day 1 – run 1 
Only one daily value accepted not used for 
evaluation 
L3 – Dataset 6 
Day 2 – run 2 
Intercept significantly different from 
0 
not used for 
evaluation 
L3 – Dataset 6 
Day 3 – run 2 
Intercept significantly different from 
0 
not used for 
evaluation 
L3 – Dataset 6 
Day 4 – run 3 
Intercept significantly different from 
0 
not used for 
evaluation 
L4 – Dataset 7 
Day 2 – run 2 
Intercept significantly different from 
0 
not used for 
evaluation 
L4 – Dataset 7 
Day 3 – run 1,2 
and 3 
Intercept significantly different from 
0 
not used for 
evaluation 
C-reactive 
protein mass 
concentration 
L3 – Dataset 6 statistical outlier, but agrees within 
uncertainty with certified values 
retained 
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Finally, the characterisation study resulted in six datasets covering twenty-two days and 
sixty-one runs. All individual accepted results of the participants are displayed in tabular form 
in Annex E. 
6.4.2 Statistical evaluation 
The number of accepted datasets were not enough to perform a normality test on the 
datasets means. The datasets means were tested for outlying means using the Grubbs test 
and using the Cochran test for outlying standard deviations, (both at a 99 % confidence 
level). Standard deviation within (swithin) and between (sbetween) laboratories were calculated 
using one-way ANOVA. The results of these evaluations are shown in Table 9. 
Table 9: Statistical evaluation of the technically accepted datasets for CRP. p: number of 
technically valid datasets 
Outliers Statistical parameters  Measurand p 
Means Variances 
Normally 
distributed Average 
[mg/L] 
s 
[mg/L] 
sbetween 
[mg/L] 
swithin 
[mg/L] 
CRP mass 
concentration 6 1 0 
Not 
enough 
datasets 
for the 
evaluation 
41.2 1.5 2.1 1.3 
 
The statistical evaluation flags laboratory L3 – Dataset 6 as outlier for CRP. However, it must 
be borne in mind that outlier tests do not take uncertainty information into consideration. A 
closer investigation reveals that the difference between the mean value of laboratory  
L3 - Dataset 6 and the other results is covered by the measurement uncertainty of laboratory 
L3 - Dataset 6. There is therefore no evidence that the results of laboratory L3 – Dataset 6 
deviate from the other results and this dataset was retained. 
The results of the characterisation campaign are presented in Figure 1. 
Figure 1: Results of the characterisation measurements for CRP. The bars represent the 
laboratory means ± 2s. The full line represents the mean of the means and the dotted lines 
represent the mean of means ± 2s. 
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The uncertainty for the characterisation exercise was estimated as the relative standard 
uncertainty of the mean of laboratory means, i.e., 
p
s
 with s the relative standard deviation 
of the mean of laboratory means and p the number of datasets, converted into a relative 
value. The relative uncertainty for the characterisation is presented in Table 10. 
Table 10: Uncertainty for the characterisation exercise. 
Measurand uchar,rel 
[%] 
CRP mass concentration 1.51 % 
 
7  Value Assignment 
For this material, a certified value has been assigned. 
Certified values are values that fulfil the highest standards of accuracy. Procedures at IRMM 
require generally pooling of not less than 6 datasets to assign certified values. Full 
uncertainty budgets in accordance with the Guide to the expression of uncertainty in 
measurement [3] must be established.  
7.1 Certified value and its uncertainties 
The unweighted mean of the means of the accepted datasets as shown in Table 9 was 
assigned as certified value for the measurand.  
The assigned uncertainty consists of uncertainties related to characterisation, uchar (see 
Section 6), potential between-unit heterogeneity, ubb (see Section 4) and potential 
degradation during transport (usts) and long-term storage, ults (see Section 5). These different 
contributions were combined to estimate the expanded, relative uncertainty of the certified 
value (UCRM, rel) with a coverage factor k as  
2
rel lts,
2
rel sts,
2
rel bb,
2
rel cal,
2
rel char,rel CRM, uuuuukU ++++⋅= . 
• uchar, rel was estimated as described in Section 6. 
• ucal, rel  is the relative standard uncertainty from ERM-DA470 [9]. 
• ubb, rel was estimated as described in Section 4. 
• usts, rel was estimated as described in section 5. As can be seen in Table 11, the 
uncertainty of degradation during dispatch is negligible compared to the other 
uncertainty contributions and is therefore not included in the final uncertainty budget. 
• ults, rel was estimated as described in Section 5.  
Because of the sufficient numbers of the degrees of freedom of the different uncertainty 
contributions, a coverage factor k of 2 was applied, to obtain the expanded uncertainties.  
The certified value and its uncertainty are summarised in Table 11. 
Table 11: Certified value and its uncertainties for ERM-DA474/IFCC 
Measurand Certified 
value [mg/L] 
uchar, rel 
[%] 
ucal, rel 
[%] 
ubb, rel 
[%] 
ults, rel 
[%] 
uCRM, rel 
[%] 
UCRM 
[mg/L] 
CRP mass 
concentration 41.2 1.51 2.42 0.69 0.61 3.00 2.5 
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8 Metrological traceability and commutability 
8.1 Metrological traceability  
Identity 
C-reactive protein in the initial solution used to spike the matrix material is a clearly defined 
analyte (identity was confirmed by Size Exclusion Chromatography, semi-native gel 
electrophoresis, 2-D gel electrophoresis and immunoassay response). The measurand in the 
spiking material is therefore structurally defined and independent of the measurement 
method. 
The participants used different methods for the final determination, different dilution buffers, 
antibodies and reagents, demonstrating absence of measurement bias. However, the 
characterisation of the matrix material ERM-DA474/IFCC was performed using only 
immunoassay-based methods and therefore the measurand is defined as C-reactive protein 
as measured by the immunoassays used in the presented procedures. 
Quantity value 
Only validated methods were used for the determination of the assigned value. The value 
assigned to the common calibrant (ERM-DA470) is traceable to the SI through calibration 
with the 1st International Standard for CRP WHO 85/506 as described in the certification 
report [9]. All relevant input parameters were calibrated with this material. The individual 
results are therefore traceable to the SI, as it is also confirmed by the agreement among the 
technically accepted datasets. As the assigned values are combinations of agreeing results 
individually traceable to the SI, the assigned quantity values themselves are traceable to the 
SI as well. 
8.2 Commutability 
Many measurement procedures include one or more steps, which are selecting specific (or 
specific groups of) analytes from the sample for the subsequent steps of the whole 
measurement process. Often the complete identity of these 'intermediate analytes' is not fully 
known or taken into account. Therefore, it is difficult to mimic all the analytically relevant 
properties of real samples within a CRM. The degree of equivalence in the analytical 
behaviour of real samples and a CRM with respect to various measurement procedures 
(methods) is summarised in a concept called 'commutability of a reference material'. There 
are various definitions expressing this concept. For instance, the CLSI Guideline C-53A [20] 
recommends the use of the following definition for the term commutability: 
"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM is essential for its fitness for use and, thus, is a crucial 
characteristic in case of the application of different measurement methods. When 
commutability of a CRM is not established in such cases, the results from routinely used 
methods cannot be legitimately compared with the certified value to determine whether a 
bias does not exist in calibration, nor can the CRM be used as a calibrator. For instance, 
CRMs intended to be used to establish or verify metrological traceability of routine clinical 
measurement procedures must be commutable for the routine clinical measurement 
procedures for which they are intended to be used. 
Commutability was assessed on the pilot batches and their dilutions up to 1/10 on the 
following platforms (Abbott Architect c8000, Abbott Architect ci8200, Hitachi 917, Olympus 
AU640, Roche Cobas 600, Roche Integra 800, Siemens BN ProSpec®) using different 
dilution buffers, antibodies and reagents. As the pilot batches prepared in the same way as 
the reference material and their dilutions were found to be commutable for the assays tested, 
it can be expected that ERM-DA474/IFCC and its subsequent dilutions (up to 1/10) is 
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commutable for the major immunoassays. However, when the material is used as a calibrant 
in a particular assay the commutability should be verified for the assay concerned. 
 
9 Instructions for use 
9.1 Storage conditions 
The materials shall be stored at -70 ± 10 °C. 
Unopened ampoules should be stored at or below -70 °C. After the opening of the ampoule it 
is advisable to store the material at 2 to 8 °C in a sealed container. Under the condition that 
any microbial contamination has been excluded, the solution of ERM-DA474/IFCC can be 
used for one week.  
Please note that the European Commission cannot be held responsible for changes that 
happen during storage of the material at the customer's premises, especially of opened 
samples. 
9.2 Safety and protection for the environment 
Each portion of donated blood used in the production of the material has been tested for the 
presence of HBs antigen, HCV antibodies, syphillis and for HIV1/HIV2 and found to be 
negative. However, the product must be handled with adequate care as any material of 
human origin. It is intended for “in vitro” measurement only. 
Avoid contact with skin. Do not discharge the waste into the drain. 
9.3 Preparation and use of the material 
To make it ready for use, the content of the ampoule has to be thawed in a water-bath at 
room temperature, while gently rotating the ampoule every 5-10 minutes, until the serum is 
thawed and the content mixed. 
9.4 Minimum sample intake 
The minimum sample intake is 20 µL.  
9.5 Use of the certified value 
The material is primarily intended to be used to calibrate serum-based protein standards and 
control materials of organisations that offer such preparations for the quantification of CRP 
by immunoassay. 
 
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [21].  
For assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is described here in brief:  
o Calculate the absolute difference between mean measured value and the certified 
value (∆m). 
o Combine measurement uncertainty (um) with the uncertainty of the  
certified value (uCRM): 22 CRMm uuu +=∆  
o Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 % 
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o If ∆m ≤ U∆ then there is no significant difference between the measurement result and 
the certified value, at a confidence level of about 95 %. 
 
Use as a calibrant 
If used as calibrant, the uncertainty of the certified value shall be taken into account in the 
estimation of the measurement uncertainty. 
Use in quality control charts 
The materials can be used for quality control charts. Different CRM-units will give the same 
result as heterogeneity was included in the uncertainties of the certified values.  
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Annexes 
Annex A: Results of the homogeneity measurements 
Figure A-1: Regression of the results in the analytical sequence order 
y = 0.0078x + 37.645
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Figure A-2: Homogeneity for CRP in ERM-DA474/IFCC. The bars are the standard deviation 
for the five replicates. 
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Annex B: Results of the short-term stability measurements 
Figure B-1: Regression of the results in the analytical sequence order 
y = 0.0016x + 38.49
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Figure B-2: Short-term stability for CRP in ERM-DA474/IFCC at 18 °C 
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Figure B-3: Short-term stability for CRP in ERM-DA474/IFCC at 4 °C 
25.0
27.0
29.0
31.0
33.0
35.0
37.0
39.0
41.0
43.0
0 1 2 3 4
Time [week]
C-
re
ac
tiv
e 
pr
o
te
in
 
[m
g/
L]
 
 
Figure B-4: Short-term stability for CRP in ERM-DA474/IFCC at -20 °C 
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Annex C: Results of the long-term stability measurements 
Figure C-1: Regression of the results in the analytical sequence order 
y = -0.0152x + 39.4
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Figure C-2: Long-term stability for CRP in ERM-DA474/IFCC at -20 °C 
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Figure C-3: Long-term stability for CRP in ERM-DA474/IFCC at -70 °C 
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Annex D: Summary of methods used in the characterisation 
Table D-1: Summary of the measurement parameters used by the participating laboratories 
Dataset Laboratory Method Instrument Dilution 
Buffer 
Antibody Reagent 
1 L1 immuno-
turbidimetry 
Hitachi 917 DAKO 
S2005 
Rabbit anti-
human CRP 
DAKO S2011 
2 L2 immuno-
nephelometry 
Siemens 
BN IITM 
N-Diluent mouse 
monoclonal anti-
human CRP 
Cardio Phase 
hs CRP 
3 L2 immuno-
nephelometry 
Siemens 
BN Prospec 
N-Diluent mouse 
monoclonal anti-
human CRP 
Cardio Phase 
hs CRP 
4 L2 immuno-
nephelometry 
Siemens 
Dimension 
Vista® 
N-Diluent mouse 
monoclonal anti-
human CRP 
Flex® reagent  
hs CRP 
5 L3 immuno-
turbidimetry 
Roche 
Integra 800 
Saline "Test-kit" 
20764930-322 
"Test-kit" 
20764930-322 
6 L3 immuno-
turbidimetry 
Roche 
Cobas c501 
Saline "Test-kit" 
04956842-190 
"Test-kit" 
04956842-190 
7 L4 immuno-
turbidimetry 
Abbott 
Architect 
c16000 
Saline CRP ultra 
reagent 2 
CRP ultra 
reagent 1 
8 L5 immuno-
turbidimetry 
Beckman 
Synchron 
Saline BCI 378020 BCI 378020 
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Annex E: Results of the characterisation measurements in mg/L 
Dataset Laboratory Day Run 1 Run 2 Run 3 
1 40.3 40.1  
2 39.7 39.6 39.2 
3 38.9 40.1 39.5 
1 L1 
4 39.1 39.5 39.7 
1 40.4 38.8 40.4 
2 39.8 41.0 39.0 
3 41.1 41.7 40.6 
2 L2 
4 39.0 39.5 42.0 
1 40.1 39.6 39.4 
2 41.0 40.6 40.0 
3 40.5 40.5 40.7 
3 L2 
4 40.7 40.4 40.9 
1 41.2 41.6 41.5 
2 39.3 39.9 41.4 
3 41.2 42.2 41.5 
4 L2 
4 41.9 41.9 41.4 
1    
2 44.6  41.6 
3 43.2  44.3 
6 L3 
4 44.1 45.7  
1 43.7 43.1 43.5 
2 40.7  40.7 
3    
7 L4 
4 40.2 40.8 40.9 
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